Bufuralol hydrochloride: Applied Assay Workflows
2026-09-05
Bufuralol hydrochloride connects β-adrenergic pharmacology with practical cardiac, animal-model, and human intestinal organoid workflows. This guide emphasizes solvent control, partial agonist-aware interpretation, and organoid-based absorption and metabolism assays.
Direct Mouse Genotyping Kit Plus: Assay-Ready DNA
2026-09-05
This scenario-based guide shows how Direct Mouse Genotyping Kit Plus, SKU K1027, can reduce upstream genotype uncertainty before mouse viability, proliferation, and cytotoxicity assays. It covers direct tissue lysis, PCR setup, interpretation, storage, and evidence-based vendor selection without overstating performance claims.
Ceruletide: Designing Mechanistic Fibrosis Assays
2026-09-04
Ceruletide, also known as Caerulein, is more than a pancreatic injury trigger: it can anchor mechanistically resolved studies of secretion, inflammation, fibrosis, and gastrointestinal motility. This guide connects assay architecture with the MFGE8–ANXA1–SMAD2/3 findings of recent regenerative research.
Superoxide as a Decision Signal in Pulmonary Fibrosis
2026-09-04
A thought-leadership guide to using superoxide measurement as a mechanistic and translational endpoint in pulmonary fibrosis research, with practical guidance for integrating a DHE-based assay into PINK1-Parkin mitophagy studies.
Hoechst 33258 Maps Tumor pH Stress to DNA State
2026-09-03
Hoechst 33258 can add a high-information DNA readout to tumor pH-disruption studies, connecting lactate transport, nuclear phenotype, and treatment response across live-cell imaging and flow cytometry. This translational framework shows how a bis-benzimide DNA stain can move beyond visualization toward mechanism-aware assay design.
Batimastat (BB-94): From MMPs to Translation
2026-09-03
A translational framework for using Batimastat (BB-94) to connect zinc-dependent MMP activity with BDNF processing, neuromuscular junction assembly, tumor invasion, angiogenesis, and experimental decision-making.
3-Deazaadenosine in m6A-Driven Liver Fibrosis
2026-09-02
A mechanistic and translational framework for using 3-Deazaadenosine hydrochloride to test whether SAHH-dependent methyl metabolism intersects with the IGF2BP1–TUBB4B–FAK pathway in hepatic stellate cell activation.
Tankyrase Inhibitors and Hippo Signaling in HCC
2026-09-02
Jia et al. showed that the tankyrase inhibitors XAV-939 and G007-LK suppress hepatocellular carcinoma cell growth while reducing YAP activity through AMOTL1 and AMOTL2 stabilization. The study connects tankyrase enzymatic activity with Hippo pathway regulation and provides a mechanistic framework for evaluating tankyrase inhibition in liver cancer models.
OSMI-1 for Reproducible OGT Inhibition
2026-09-01
Learn how OSMI-1 (SKU B7923) can support controlled O-GlcNAc transferase inhibition in viability, cytotoxicity, and mechanistic cell assays. This scenario-based guide connects biochemical potency, cellular toxicity, solvent handling, target engagement, and interpretation limits to practical laboratory decisions.
Merimepodib (VX-497) for IMPDH Assays
2026-09-01
Merimepodib (VX-497) links IMPDH inhibition to guanine-nucleotide depletion, enabling targeted cell-proliferation, immune-cell, and antiviral workflows. This guide translates PEDV metabolism findings into practical assay design, controls, dosing logic, and troubleshooting strategies.
Glycogen Colorimetric Assay Kit II for Metabolism
2026-08-31
The Glycogen Colorimetric Assay Kit II converts glycogen into a measurable glucose-derived color signal, enabling sensitive analysis of liver, muscle, and other complex biological samples. Its interference-aware design is particularly useful for circadian exercise studies, diabetes research, glycogen storage disease research, and high-throughput metabolic screening.
LY364947 for TGF-β and EMT Research
2026-08-30
LY364947 is a selective TGF-β type I receptor kinase inhibitor for separating receptor-driven Smad2 signaling from parallel EMT and Wnt/β-catenin effects. This workflow-focused guide shows how to use it as a pathway-control compound in cancer, fibrosis, and retinal injury models while improving solubility, assay timing, and interpretation.
Palonosetron in CINV: Pharmacology and Clinical Evidence
2026-08-29
Ruhlmann and Herrstedt’s review examines why palonosetron hydrochloride became an important 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting. Its prolonged activity, high receptor affinity, and distinctive allosteric pharmacology may improve protection against delayed emesis, although clinical benefit depends on chemotherapy risk, combination therapy, and the outcome being measured.
JSH-23 Workflows for NF-κB Inflammation Research
2026-08-29
JSH-23 is a mechanism-focused NF-κB inhibitor for separating p65 nuclear transcription from upstream IκB degradation. This guide translates that distinction into cell-based, infection-related, and kidney injury workflows with practical controls, assay choices, and troubleshooting steps.
Paroxetine Mesylate Research Workflows
2026-08-28
Paroxetine Mesylate supports exposure-controlled studies spanning SERT pharmacology, CYP2D6 liability, and emerging colorectal cancer models. This guide converts its multi-target profile into practical assay workflows, dose-selection logic, and troubleshooting strategies for reproducible research.
459 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page